ClinicalTrials.gg
CompletedNCT01693029ACCESSUpdated Jul 2, 2017Results posted

Study to Compare Safety and Efficacy of HX575 Epoetin Alfa and US-licensed Epoetin Alfa

A Phase 3 interventional study of HX575 epoetin alfa and US-licensed epoetin alfa in Anemia and Chronic Kidney Disease (CKD), sponsored by Sandoz. Completed at 52 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-07-02.

Sponsored by Sandoz (formerly part of Novartis) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
435
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 19 studies in Anemia by Novartis — 1 open to participants now, 2 under way, 2 of them phase 3. Anemia · Novartis.

Enrollment
4th of 17
435 · median 97
Started
2012
the only one that year
Phase 3
12 of 19
1 open now
Registered
11th of 19
by date

Among the 19 studies in Anemia by Novartis, this one is the 4th largest by enrollment of the 17 interventional ones that give a count, is the only one that started in 2012, is one of 12 in phase 3, and was the 11th registered.

Anemia

1,810 studies on the registry are indexed under Anemia; 215 are open to participants now.

Browse Anemia studies →

Open to participants now

1 of the 19 studies in Anemia by Novartis is open now, in 6 countries. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 122 Anemia studies recruiting now, 67 (55%) set no upper age limit and 37 (30%) stop at 75 or younger; 34 take children under 18; 23 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies in Anemia by Novartis, or all of them as a file.
02

Study summary

The purpose of this study is to show biosimilarity of HX575 epoetin alfa with the US licensed reference product Epogen®/Procrit® when applied subcutaneously. This study is intended to generate data supporting that the efficacy and safety under treatment with HX575 and Epogen®/Procrit® are comparable.

Read the detailed description

This is a randomized, double-blind, parallel-group, multicenter study to evaluate the efficacy and safety of HX575 epoetin alfa vs. US-licensed epoetin alfa (Epogen®/Procrit®) in the treatment of anemia associated with chronic kidney disease (CKD).

03

Conditions studied

  • Anemia
  • Chronic Kidney Disease (CKD)

Keywords

  • erythropoietin alfa
  • CKD 5d
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with end stage renal disease (stage CKD 5d), receiving stable subcutaneous maintenance therapy with Epogen® or Procrit® at least once per week
  • Mean level between 9.0 - 11.5 g/dL during the screening period
  • Adequate iron substitution

Exclusion criteria

Exclusion Criteria:

  • for Erythropoiesis Stimulating Agent (ESA) therapy
  • History of Pure Red Cell Aplasia (PRCA), or anti-erythropoietin (EPO) antibodies
  • Known (HIV) or infection
  • infection on an active treatment
  • Symptomatic congestive heart failure ( [NYHA] class III and IV)
  • Unstable angina pectoris, or cardiac infarction during the last 6 months prior to randomization
  • Percutaneous coronary intervention, or coronary artery bypass grafting during the last 6 months prior to randomization
  • History of of any organ system
  • Systemic lupus erythematous
  • Immunocompromized patients

Other In-/Exclusion criteria may apply

Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
435 participants (actual)

Study arms

  • Experimental
    HX575 epoetin alfa

    HX575, recombinant human epoetin alfa

    Drug: HX575 epoetin alfa

  • Active comparator
    US-licensed epoetin alfa

    US-licensed recombinant human epoetin alfa

    Drug: US-licensed epoetin alfa

Interventions

  • DrugHX575 epoetin alfa

    Solution for subcutaneous injection. The drug is administered subcutaneously at least once per week over 52 weeks. The dose will be individually titrated to maintain hemoglobin levels between 10 to 11 g/dL.

    Also known as: Binocrit® (Europe), Epoetin alfa HEXAL® (Europe), Abseamed® (Europe)

  • Solution for subcutaneous injection.

    Also known as: Epogen®, Procrit®

06

What researchers measure

Primary outcomes

  1. Mean Absolute Change in Hemoglobin Levels Between the Screening/Baseline Period (Week -4 to Day 1) and the Evaluation Period (Week 21-28)

    Response to epoetin alfa in anemic patients with chronic renal failure is manifested by increased hematocrit, hemoglobin, reduced transfusion requirements and increase in quality of life. Hemoglobin (laboratory haematology parameter) is the primary endpoint of the study .

    Time frame: Week -4 to Day1 and Week 21-28

  2. Change in Mean Hb Level Between Baseline (Week -4 to Day1) and Evaluation Period (Week 21-28)

    Response to epoetin alfa in anemic patients with chronic renal failure is manifested by increased hematocrit, hemoglobin, reduced transfusion requirements and increase in quality of life. Hemoglobin (laboratory haematology parameter) is the primary endpoint of the study .

    Time frame: Week -4 to Day1 and Week 21-28

Secondary outcomes

  1. Mean Weekly Dose During Evaluation Period (Week 21-28)

    Mean weekly study drug dose during evaluation period (Week 21-28)

    Time frame: Week 21-28

  2. Incidence of Antibody Formation Against Epoetin

    Number of patients with positive antidrug antibody (ADA) finding at any time during their treatment period. Count includes 2 patients (1 in each arm) that already had a positive ADA Baseline finding. ADA testing performed by by Radio-Immuno-Precipitation assay. No patient developed neutralizing antibodies.

    Time frame: 52 weeks

07

Results

Posted May 12, 2017

Participant flow

Participant flow — Overall Study
MilestoneHX575 Epoetin AlfaUS-licensed Epoetin Alfa
Started217218
Completed173161
Not completed4457
Withdrew: Withdrawal by subject1522
Withdrew: Kidney transplantation77
Withdrew: Bindinging anti-epo antibodies62
Withdrew: Protocol violation67
Withdrew: Change in dialysis modality21
Withdrew: Physician decision02
Withdrew: Lost to follow-up01
Withdrew: Adverse event16
Withdrew: Death58
Withdrew: Non-compliance21

Outcome measures

PrimaryMean Absolute Change in Hemoglobin Levels Between the Screening/Baseline Period (Week -4 to Day 1) and the Evaluation Period (Week 21-28)

Response to epoetin alfa in anemic patients with chronic renal failure is manifested by increased hematocrit, hemoglobin, reduced transfusion requirements and increase in quality of life. Hemoglobin (laboratory haematology parameter) is the primary endpoint of the study .

Time frame:
Week -4 to Day1 and Week 21-28
Reported as:
Least squares mean · g/dL
Mean Absolute Change in Hemoglobin Levels Between the Screening/Baseline Period (Week -4 to Day 1) and the Evaluation Period (Week 21-28)
g/dLHX575 Epoetin AlfaUS-licensed Epoetin Alfa
Mean Absolute Change in Hemoglobin Levels Between the Screening/Baseline Period (Week -4 to Day 1) and the Evaluation Period (Week 21-28)-0.0960 ± 0.0575-0.0035 ± 0.0573
Statistical analysis
  • HX575 Epoetin Alfa vs US-licensed Epoetin Alfa · Mean difference (final values): -0.0926 · 90% CI -0.2264 to 0.0413
PrimaryChange in Mean Hb Level Between Baseline (Week -4 to Day1) and Evaluation Period (Week 21-28)

Response to epoetin alfa in anemic patients with chronic renal failure is manifested by increased hematocrit, hemoglobin, reduced transfusion requirements and increase in quality of life. Hemoglobin (laboratory haematology parameter) is the primary endpoint of the study .

Time frame:
Week -4 to Day1 and Week 21-28
Reported as:
Mean · g/dL
Change in Mean Hb Level Between Baseline (Week -4 to Day1) and Evaluation Period (Week 21-28)
g/dLHX575 Epoetin AlfaUS-licensed Epoetin Alfa
Baseline period10.53 ± 0.63510.50 ± 0.615
Evaluation period10.42 ± 0.82610.51 ± 0.873
Change from baseline period to evaluation period-0.11 ± 1.0110.01 ± 0.953
SecondaryMean Weekly Dose During Evaluation Period (Week 21-28)

Mean weekly study drug dose during evaluation period (Week 21-28)

Time frame:
Week 21-28
Reported as:
Mean · international units
Mean Weekly Dose During Evaluation Period (Week 21-28)
international unitsHX575 Epoetin AlfaUS-licensed Epoetin Alfa
Mean Weekly Dose During Evaluation Period (Week 21-28)5876.5 ± 5785.505804.0 ± 6343.70
SecondaryIncidence of Antibody Formation Against Epoetin

Number of patients with positive antidrug antibody (ADA) finding at any time during their treatment period. Count includes 2 patients (1 in each arm) that already had a positive ADA Baseline finding. ADA testing performed by by Radio-Immuno-Precipitation assay. No patient developed neutralizing antibodies.

Time frame:
52 weeks
Reported as:
Count of participants · Participants
Incidence of Antibody Formation Against Epoetin
ParticipantsHX575 Epoetin AlfaUS-licensed Epoetin Alfa
Incidence of Antibody Formation Against Epoetin72

Adverse events

Collected over Adverse events were collected from the date of informed consent until the end of the treatment period, for approximately 1 year.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
HX575 Epoetin Alfa5/217 (2.3%)91/217 (41.9%)112/217 (51.6%)
US-licensed Epoetin Alfa11/218 (5%)90/218 (41.3%)123/218 (56.4%)
Most frequent serious events
Showing 10 of 185
Most frequent serious events
EventHX575 Epoetin AlfaUS-licensed Epoetin Alfa
PneumoniaInfections and infestations9/21710/218
Cardiac failure congestiveCardiac disorders8/2174/218
HyperkalaemiaMetabolism and nutrition disorders8/2177/218
Fluid overloadMetabolism and nutrition disorders6/2178/218
CellulitisInfections and infestations7/2177/218
Atrial fibrillationCardiac disorders3/2177/218
HypoglycaemiaMetabolism and nutrition disorders3/2177/218
Non-cardiac chest painGeneral disorders6/2172/218
AnaemiaBlood and lymphatic system disorders4/2176/218
PeritonitisInfections and infestations5/2173/218
Most frequent other events
Showing 10 of 20
Most frequent other events
EventHX575 Epoetin AlfaUS-licensed Epoetin Alfa
HypertensionVascular disorders24/21727/218
Upper respiratory tract infectionInfections and infestations12/21722/218
DiarrhoeaGastrointestinal disorders21/21719/218
NauseaGastrointestinal disorders17/21720/218
FallInjury, poisoning and procedural complications13/21718/218
Pain in extremityMusculoskeletal and connective tissue disorders12/21716/218
Arteriovenous fistula site complicationInjury, poisoning and procedural complications15/21711/218
HeadacheNervous system disorders15/21715/218
VomitingGastrointestinal disorders10/21715/218
DyspnoeaRespiratory, thoracic and mediastinal disorders9/21715/218

Baseline characteristics

Age, Continuous
Age, Continuous(years)HX575 Epoetin AlfaUS-licensed Epoetin AlfaTotal
Mean59.8 ± 13.7657.6 ± 13.4058.7 ± 13.61
Sex: Female, Male
Sex: Female, Male(Participants)HX575 Epoetin AlfaUS-licensed Epoetin AlfaTotal
Female82103185
Male135115250
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)HX575 Epoetin AlfaUS-licensed Epoetin AlfaTotal
Hispanic or Latino9593188
Not Hispanic or Latino122125247
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)HX575 Epoetin AlfaUS-licensed Epoetin AlfaTotal
American Indian or Alaska Native11516
Asian61319
Native Hawaiian or Other Pacific Islander404
Black or African American5772129
White139128267
More than one race000
Unknown or Not Reported000
Region of Enrollment
Region of Enrollment(participants)HX575 Epoetin AlfaUS-licensed Epoetin AlfaTotal
United States217218435
Height
Height(cm)HX575 Epoetin AlfaUS-licensed Epoetin AlfaTotal
Mean167.2 ± 10.17166.0 ± 10.33166.6 ± 10.26
Weight
Weight(kg)HX575 Epoetin AlfaUS-licensed Epoetin AlfaTotal
Mean82.8 ± 20.7586.5 ± 24.3284.6 ± 22.66
BMI
BMI(kg/m^2)HX575 Epoetin AlfaUS-licensed Epoetin AlfaTotal
Mean29.55 ± 6.87231.41 ± 8.78330.48 ± 7.933

5 further baseline measures are reported on the registry.

08

Study locations

52 sites
  • Southwestern Kidney Institute
    Tempe, Arizona 85284, United States
  • North America Research Institute
    Azusa, California 91702, United States
  • Pegasus Dialysis, LLC
    Bakersfield, California 93308, United States
  • Central Nephrology Medical Group
    Bakersfield, California 93309, United States
  • California Institute of Renal Research
    Chula Vista, California 91910, United States
  • Renal Consultants Medical Group
    Granada Hills, California 91344, United States
  • Angel Kidney Care of Inglewood Dialysis Center
    Inglewood, California 90301, United States
  • California Institute of Renal Research
    La Mesa, California 91942, United States
  • Alliance Research Centers
    Laguna Hills, California 92653, United States
  • Academic Medical Research Institute
    Los Angeles, California 90022, United States
  • Ronald Reagan Medical Center, Department of Pharmaceutical Services, Drug Information Center
    Los Angeles, California 90025, United States
  • Tower Nephrology Medical Group
    Los Angeles, California 90048, United States
  • St Vincent Dialysis Center
    Los Angeles, California 90057, United States
  • Kidney Research Center
    Lynwood, California 90262, United States
  • Valley Renal Medical Group
    Northridge, California 91324, United States
  • Ontario Dialysis, Inc.
    Ontario, California 91762, United States
  • Apex Research of Riverside
    Riverside, California 92505, United States
  • Capital Nephrology Medical Group
    Sacramento, California 95825, United States
  • California Institute of Renal Research
    San Diego, California 92111, United States
  • La Jolla Clinical Research, Inc.
    San Diego, California 92154, United States
  • North America Research Institute
    San Dimas, California 91773, United States
  • American Institute of Research
    Whittier, California 90603, United States
  • South Florida Nephrology
    Coral Springs, Florida 33071, United States
  • Pines Clinical Research Inc.
    Hollywood, Florida 33020, United States
  • Genesis Clinical Research Corporation
    Tampa, Florida 33614, United States
  • Atekha Nephrology Clinic LLC
    Statesboro, Georgia 30458, United States
  • Four Rivers Clinical Research, Incorporated
    Paducah, Kentucky 42003, United States
  • Northwest Louisana Nephrology
    Shreveport, Louisiana 71101, United States
  • Germantown Dialysis
    Germantown, Maryland 20874, United States
  • Fresenius Management Services, Inc.
    Farmington, Missouri 63640, United States
  • Creighton University
    Omaha, Nebraska 68131, United States
  • Kidney Specialists of Southern Nevada
    Las Vegas, Nevada 89106, United States
  • Seacoast Kidney and Hypertension Specialist, PLLC
    Portsmouth, New Hampshire 03801, United States
  • Renal Medicine Associates
    Albuquerque, New Mexico 87109, United States
  • New York Hospital Queens
    Fresh Meadows, New York 11365, United States
  • Metrolina Nephrology Associates, PA
    Charlotte, North Carolina 28207, United States
  • Boice-Willis Clinic, PA
    Rocky Mount, North Carolina 27804, United States
  • Southeastern Dialysis Center
    Wilmington, North Carolina 28401, United States
  • Northeast Clinical Research Centers, Inc.
    Bethlehem, Pennsylvania 18017, United States
  • Delaware Valley Nephrology and Hypertension Associates, PC
    Philadelphia, Pennsylvania 19118, United States
  • Rhode Island Hospital
    Providence, Rhode Island 02903, United States
  • Palmetto Nephrology PA
    Orangeburg, South Carolina 29118, United States
  • SC Nephrology & Hypertension Center, Inc.
    Orangeburg, South Carolina 29118, United States
  • Knoxville Kidney Center PLLC
    Knoxville, Tennessee 37923, United States
  • Research Management, Inc.
    Austin, Texas 78756, United States
  • Gamma Clinical Research Institute
    Edinburg, Texas 78539, United States
  • Nephrology, P.A.
    Houston, Texas 77030, United States
  • Clinical Trial Network
    Houston, Texas 77074, United States
  • Renal Associates, PA
    San Antonio, Texas 78215-2035, United States
  • Southern Utah Kidney and Hypertension Center
    Saint George, Utah 84770, United States
  • Mendez Center For Clinical Research, LLC
    Alexandria, Virginia 22304, United States
  • West Virginia University Hospitals and Clinic
    Morgantown, West Virginia 26506, United States
09

References and documents

Publications

  • Weir MR, Pergola PE, Agarwal R, Fink JC, Kopyt NP, Singh AK, Kumar J, Schmitt S, Schaffar G, Rudy A, McKay JP, Kanceva R. A Comparison of the Safety and Efficacy of HX575 (Epoetin Alfa Proposed Biosimilar) with Epoetin Alfa in Patients with End-Stage Renal Disease. Am J Nephrol. 2017;46(5):364-370. doi: 10.1159/000481736. Epub 2017 Oct 30. PubMed 29084409 ↗

Individual participant data

Plan to share: Undecided

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2012, a primary completion of May 2014 and a completion of Mar 2015. It does not say whether these dates are actual or estimated.

Results were first posted in May 2017, 3 years after primary completion. A results delay was requested in May 2015.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 21, 2012
First posted
Sep 26, 2012
Start
Sep 2012
Primary completionActual
May 2014
CompletionActual
Mar 2015
Results delay requested
May 4, 2015
Results first posted
May 12, 2017
Last update
Jul 2, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 2, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01693029
Lead sponsor
Sandoz
Responsible party
Sponsor
First posted
Sep 26, 2012
Start date
Sep 2012
Primary completion
May 2014
Completion
Mar 2015
Results posted
May 12, 2017
Last update
Jul 2, 2017

Study contacts

Sandoz Biopharmaceutical Clinical Development
study director · Sandoz Biopharmaceuticals

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion